One Case of Immune-Related Myocardial Injury Caused by Glofitamab Injection

doi:10.19803/j.1672-8629.20250696

Abstract

Abstract: Objective To investigate immune-related myocardial injury induced by glofitamab in order to provide a reference for safe clinical use. Methods Immune-related myocardial injury induced by glofitamab in a patient with diffuse large B-cell lymphoma was analyzed while related literature was summarized. Results Based on the patient’s clinical manifestations, results of laboratory tests, and the temporal association with drug administration, the immune-related myocardial injury was considered to be strongly associated with glofitamab. After comprehensive management involving dexamethasone, tocilizumab, continuous renal replacement therapy, trimetazidine, rosuvastatin, and isosorbide mononitrate, the patient improved and was discharged. Conclusion Despite the seemingly low incidence of glofitamab-induced immune-related myocardial injury, the associated mortality can be exceedingly high. Prior to glofitamab therapy, potential risks should be assessed, and during treatment, patients should be closely monitored for the risk of immune-related myocardial injury.

Key words: Glofitamab, Bispecific Antibody, Diffuse Large B-Cell Lymphoma, Cytokine Release Syndrome, Immune-related Myocardial Injury, Dexamethasone, Continuous Renal Replacement Therapy, Adverse Drug Reactions

CLC Number:

YU Lingzi, HE Jiajie, PING Nana, ZHU Qian, ZHANG Xiao, LI Junhong, ZOU Rui, HE Siyun, XIA Fan, JIN Zhengming, QU Changju. One Case of Immune-Related Myocardial Injury Caused by Glofitamab Injection[J]. Chinese Journal of Pharmacovigilance, 2026, 23(2): 200-202.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20250696

https://zgywjj.magtechjournal.com/EN/Y2026/V23/I2/200

References

[1] DICKINSON MJ, CARLO-STELLA C, MORSCHHAUSER F, et al.Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. N Engl J Med, 2022, 387(24): 2220-2231.
[2] SONG YQ, ZHANG HL, HUANG HQ, et al.Glofitamab Monotherapy Induces High Complete Response Rates and Manageable Safety in Chinese Patients with Heavily Pretreated Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. Haematologica, 2024, 109(4): 1269-1273.
[3] SHUMILOV E, WURM-KUCZERA R, KERKHOFF A, et al.Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study[J]. Blood Adv, 2025, 9(15): 3865-3877.
[4] SAYED A, MUNIR M, GHAZI SM, et al.Cardiovascular Toxicities Associated with Bispecific T-Cell Engager Therapy[J]. J Immunother Cancer, 2024, 12(2): E008518.
[5] HUTCHINGS M, MORSCHHAUSER F, IACOBONI G, et al.Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: a Phase I Trial[J]. J Clin Oncol, 2021, 39(18): 1959-1970.
[6] LEE DW, SANTOMASSO BD, LOCKE FL, et al.ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells[J]. Biol Blood Marrow Transplant, 2019, 25(4): 625-638.
[7] CHEN PX, TANG Y, HE WX, et al.Potential Pathophysiological Mechanisms Underlying Multiple Organ Dysfunction in Cytokine Release Syndrome[J]. Mediators Inflamm, 2022, 2022: 7137900.
[8] MUNIR M, SAYED A, ADDISON D, et al.Cardiovascular Toxicities Associated with Novel Cellular Immune Therapies[J]. Blood Adv, 2024, 8(24): 6282-6296.
[9] MORRIS EC, NEELAPU SS, GIAVRIDIS T, et al.Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy[J]. Nat Rev Immunol, 2021, 22(2): 85-96.
[10] ALVI RM, FRIGAULT MJ, FRADLEY MG, et al.Cardiovascular Events among Adults Treated with Chimeric Antigen Receptor T-Cells (CAR-T)[J]. J Am Coll Cardiol, 2019, 74(25): 3099-3108.
[11] LIU L, YAO WT, WANG M, et al. A Systematic Review of Cardiovascular-Toxicities Induced by Cancer Immune Therapies: Underlying Mechan-isms, Clinical Manifestations and Therapeutic Approaches[J]. Semin Cancer Biol, 2024, 106-107: 179-191.
[12] SHALABI H, SACHDEV V, KULSHRESHTHA A, et al.Impact of Cytokine Release Syndrome on Cardiac Function Following CD19 CAR-T Cell Therapy in Children and Young Adults with Hematological Malignancies[J]. J Immunother Cancer, 2020, 8(2): E001159.
[13] CROMBIE JL, GRAFF T, FALCHI L, et al.Consensus Recommen-dations on the Management of Toxicity Associated with CD3×CD20 Bispecific Antibody Therapy[J]. Blood, 2024, 143(16): 1565-1575.
[14] CONSTANTINESCU C, PASCA S, TAT T, et al.Continuous Renal Replacement Therapy in Cytokine Release Syndrome Following Immunotherapy or Cellular Therapies?[J]. J Immunother Cancer, 2020, 8(1): E000742.
[15] SRINIVASAN SRIDHAR V, CHEN M, GERSON H, et al.Variation of High-Sensitivity Troponin T Results in Patients Undergoing Continuous Renal Replacement Therapy[J]. Can J Kidney Health Dis, 2019, 6: 2054358119828386.